Art. -Nr.: HY-17545

LGK974

Name: LGK974
Brand: MedChemExpress
SKU: HY-17545
Price: 120.00 USD
Availability: InStock
Rating: 5 (47 reviews)

(Synonyms: WNT974)

47 Cited Publications

Kundenbewertung

Based on 47 publication(s) in Google Scholar

LGK974 (WNT974) is an orally bioavailable and specific Porcupine (PORCN) inhibitor with an IC₅₀ of 0.1 nM.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.96%
CAS. Nr.: 1243244-14-5
Formel: C₂₃H₂₀N₆O
Molecular Weight:396.44

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

LGK974 Chemical Structure

CAS. Nr.: 1243244-14-5

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (47)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

LGK974 (WNT974) is an orally bioavailable and specific Porcupine (PORCN) inhibitor with an IC₅₀ of 0.1 nM^[1].

IC₅₀ & Target

Porcupine^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
Caco-2	CC₅₀	7.61 μM Compound: LGK-974	Toxicity against Caco-2 cells determined at 48 hours by intracellular ATP concentration using the CellTiter-Glo Luminescent Cell Viability Assay Toxicity against Caco-2 cells determined at 48 hours by intracellular ATP concentration using the CellTiter-Glo Luminescent Cell Viability Assay	10.21203/rs.3.rs-23951/v1
Caco-2	IC₅₀	3.27 μM Compound: LGK-974	Determination of IC50 values for inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells after 48 hours by high content imaging Determination of IC50 values for inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells after 48 hours by high content imaging	10.21203/rs.3.rs-23951/v1
HCT-116	IC₅₀	>100 μM Compound: LGK974	Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by MTS assay Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by MTS assay	[PMID: 34382808]
HEK293	IC₅₀	0.9 nM Compound: LGK974	Inhibition of Wnt signaling (unknown origin) expressed in mouse L Wnt3A cells co-cultured with HEK293 cells after 48 hrs by Super-top flash reporter gene assay Inhibition of Wnt signaling (unknown origin) expressed in mouse L Wnt3A cells co-cultured with HEK293 cells after 48 hrs by Super-top flash reporter gene assay	[PMID: 26647303]
HEK293	IC₅₀	0.9 nM Compound: LGK974	Inhibition of porcupine in mouse L Wnt3A cells co-cultured with HEK293 cells after 48 hrs by Super-top flash reporter gene assay Inhibition of porcupine in mouse L Wnt3A cells co-cultured with HEK293 cells after 48 hrs by Super-top flash reporter gene assay	[PMID: 27692509]
HT-1080	IC₅₀	0.4 nM Compound: LGK974	Inhibition of porcupine activity (unknown origin) expressed in human HT1080 cells assessed as suppression of Wnt3A-mediated super top flash activity by STF luciferase assay Inhibition of porcupine activity (unknown origin) expressed in human HT1080 cells assessed as suppression of Wnt3A-mediated super top flash activity by STF luciferase assay	[PMID: 26522946]
MCF-10A	IC₅₀	>100 μM Compound: LGK974	Cytotoxicity against human MCF-10A cells assessed as cell growth inhibition measured after 72 hrs by MTS assay Cytotoxicity against human MCF-10A cells assessed as cell growth inhibition measured after 72 hrs by MTS assay	[PMID: 34382808]
MDA-MB-231	IC₅₀	>100 μM Compound: LGK974	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 72 hrs by MTS assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 72 hrs by MTS assay	[PMID: 34382808]
MDA-MB-468	IC₅₀	>100 μM Compound: LGK974	Antiproliferative activity against human MDA-MB-468 cells assessed as cell growth inhibition measured after 72 hrs by MTS assay Antiproliferative activity against human MDA-MB-468 cells assessed as cell growth inhibition measured after 72 hrs by MTS assay	[PMID: 34382808]
SW480	IC₅₀	>100 μM Compound: LGK974	Antiproliferative activity against human SW480 cells assessed as cell growth inhibition measured after 72 hrs by MTS assay Antiproliferative activity against human SW480 cells assessed as cell growth inhibition measured after 72 hrs by MTS assay	[PMID: 34382808]

In Vitro

LGK974 effectively displaces [³H]-GNF-1331 with an IC₅₀ of 1 nM in the PORCN radioligand binding assay. LGK974 potently reduces Wnt-dependent AXIN2 mRNA levels in HN30 cells with an IC₅₀ of 0.3 nM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

LGK974, a drug that targets Porcupine, a Wnt-specific acyltransferase. LGK974 potently inhibits Wnt signaling, has strong efficacy in rodent tumor models, and is well-tolerated. Toxicology studies are performed on nontumor bearing rats at 3 and 20 mg/kg. At the efficacious dose of 3 mg/kg per day for 14 d, LGK974 is well-tolerated without abnormal histopathological findings in Wnt-dependent tissues, including the intestine, stomach, and skin. When rats are administrated a very high dose of 20 mg/kg per day for 14 d, loss of intestinal epithelium is observed, consistent with the concept that Wnt is required for intestinal tissue homeostasis^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 1243244-14-5
Appearance Solid
Molecular Weight 396.44
Formel C₂₃H₂₀N₆O
Color Off-white to pink
SMILES

O=C(NC1=NC=C(C2=NC=CN=C2)C=C1)CC3=CN=C(C4=CC(C)=NC=C4)C(C)=C3
Synonyms

WNT974
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (47)

All Histological Imaging/StainingIn Vivo Efficacy StudyWBIF

Sort by:

Journal Impact Factor

Cancer Cell

CD44+ lung cancer stem cell-derived pericyte-like cells cause brain metastases through GPR124-enhanced trans-endothelial migration. [Abstract]

2023 Sep 11;41(9):1621-1636.e8. PMID: 37595587
Nature

A Wnt-producing niche drives proliferative potential and progression in lung adenocarcinoma. [Abstract]

2017 May 18;545(7654):355-359. PMID: 28489818
Cell

2026 Jun 25;189(13):3903-3921.e26. PMID: 42242224
Bioact Mater

Turning gray selenium into a nanoaccelerator of tissue regeneration by PEG modification. [Abstract]

2022 Jan 2:15:131-144. PMID: 35386336
Cell Stem Cell

Lymphatics and fibroblasts support intestinal stem cells in homeostasis and injury. [Abstract]

2022 Aug 4;29(8):1246-1261.e6. PMID: 35931033
Cell Stem Cell

Distinct Spatiotemporally Dynamic Wnt-Secreting Niches Regulate Proximal Airway Regeneration and Aging. [Abstract]

2020 Sep 3;27(3):413-429.e4. PMID: 32721381

LGK974 purchased from MedChemExpress. Usage Cited in: Cell Stem Cell. 2020 Sep 3;27(3):413-429.e4. [Abstract]

IF images of uninjured, 48 hpi, and 72 hpi mouse airway epithelia wild-type mice treated with vehicle or LGK974 assessing BrdU incorporation. Relative to vehicle-treated mice, LGK974-treated mice exhibited an attenuated SAE with few BrdU+ ABSCs, thereby phenocopying the repair response of K5-CreER;Ctnnb1fl/fl mouse tracheas.
Nat Commun

FBXW2 suppresses migration and invasion of lung cancer cells via promoting β-catenin ubiquitylation and degradation. [Abstract]

2019 Mar 27;10(1):1382. PMID: 30918250
Exp Mol Med

LGK974 suppresses lipopolysaccharide-induced endotoxemia in mice by modulating the crosstalk between the Wnt/β-catenin and NF-κB pathways. [Abstract]

2021 Mar;53(3):407-421. PMID: 33692475

LGK974 purchased from MedChemExpress. Usage Cited in: Exp Mol Med. 2021 Mar;53(3):407-421. [Abstract]

C57BL/6 mice were injected i.p. with 0–60 mg/kg LGK974 2 h before being injected with 25 mg/kg LPS. Cytokine concentrations in the plasma were determined using a magnetic Luminex assay.
Sci Immunol

Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape. [Abstract]

2021 Nov 12;6(65):eabc6424. PMID: 34767457
Nat Chem Biol

Tegavivint triggers TECR-dependent nonapoptotic cancer cell death. [Abstract]

2025 May 26. PMID: 40419770
J Clin Invest

Targeting Wnt/β-Catenin and circadian regulator restores PRC2/EZH2 controlled chromatin bivalency and suppresses cell state diversity. [Abstract]

2026 Mar 17:e200260. PMID: 41842971
Adv Sci (Weinh)

Opsin-Free Activation of Bmp Receptors by a Femtosecond Laser. [Abstract]

2024 Mar;11(10):e2308072. PMID: 38239021
Neuro Oncol

Wnt Signaling Regulates MFSD2A-dependent Drug Delivery through Endothelial Transcytosis in Glioma. [Abstract]

2023 Jun 2;25(6):1073-1084. PMID: 36591963

LGK974 purchased from MedChemExpress. Usage Cited in: Neuro Oncol. 2023 Jun 2;25(6):1073-1084. [Abstract]

LGK974 (2.5 mg/kg; 4 days; i.g.). Immunohistochemical staining of CD31 in RCAS/tv-a glioma from mice treated with or without LGK974 was performed.

LGK974 purchased from MedChemExpress. Usage Cited in: Neuro Oncol. 2023 Jun 2;25(6):1073-1084. [Abstract]

LGK974 (2.5 mg/kg; 4 days; i.g.). Co-immunofluorescence staining and quantification of β-catenin and CD31 in RCAS/tv-a glioma tumors from mice treated with or without LGK974 were performed.

LGK974 purchased from MedChemExpress. Usage Cited in: Neuro Oncol. 2023 Jun 2;25(6):1073-1084. [Abstract]

LGK974 (2.5 mg/kg; 4 days; i.g.) was administered. The survival curve of CT-2A glioma-bearing mice treated with LGK974 and/or TMZ was analyzed.
Cancer Lett

CircPTK2/PABPC1/SETDB1 axis promotes EMT-mediated tumor metastasis and gemcitabine resistance in bladder cancer. [Abstract]

2023 Feb 1:554:216023. PMID: 36436682
Oncogene

Exosomal Wnt-induced dedifferentiation of colorectal cancer cells contributes to chemotherapy resistance. [Abstract]

2019 Mar;38(11):1951-1965. PMID: 30390075
Cell Chem Biol

STT3A is essential for Wnt signaling and represents a target for cancers driven by RNF43 deficiency. [Abstract]

2025 Oct 22:S2451-9456(25)00306-X. PMID: 41130209
Clin Transl Med

WNT5B drives osteosarcoma stemness, chemoresistance and metastasis. [Abstract]

2024 May;14(5):e1670. PMID: 38689429
Br J Cancer

Nuclear FGF2, androgen receptor and Wnt pathway activation define a targetable subset of antiprogestin-resistant luminal breast cancer. [Abstract]

2026 Jun;134(11):1671-1682. PMID: 41935240
Cell Rep

Modeling human ectopic pregnancies with trophoblast and vascular organoids. [Abstract]

2023 May 23;42(6):112546. PMID: 37224015
Cell Mol Neurobiol

2026 Jan 24;46(1):36.
Neurotherapeutics

Blockers of Wnt3a, Wnt10a, or β-Catenin Prevent Chemotherapy-Induced Neuropathic Pain In Vivo. [Abstract]

2021 Jan;18(1):601-614. PMID: 33128175
Cancer Cell Int

BRF2 is mediated by microRNA-409-3p and promotes invasion and metastasis of HCC through the Wnt/β-catenin pathway. [Abstract]

2023 Mar 16;23(1):46. PMID: 36927769
Drug Des Devel Ther

Dual Targeting of Cell Growth and Phagocytosis by Erianin for Human Colorectal Cancer. [Abstract]

2020 Aug 12:14:3301-3313. PMID: 32848368
Commun Biol

Wnt11 mediates fibroblast-smooth muscle cell interaction to promote neurogenic bladder fibrosis in rats. [Abstract]

2026 Feb 9;9(1):194. PMID: 41663583
Int Immunopharmacol

LGK974 suppresses the formation of deep vein thrombosis in mice with sepsis. [Abstract]

2024 Jan 25:127:111458. PMID: 38160565
Int J Mol Sci

Wnt3a Facilitates SARS-CoV-2 Pseudovirus Entry into Cells. [Abstract]

2023 Dec 22;25(1):217. PMID: 38203386
Int J Mol Sci

Wnt Signaling Inhibitors and Their Promising Role in Tumor Treatment. [Abstract]

2023 Apr 4;24(7):6733. PMID: 37047705
Mol Neurobiol

Teriflunomide Promotes Blood-Brain Barrier Integrity by Upregulating Claudin-1 via the Wnt/β-catenin Signaling Pathway in Multiple Sclerosis. [Abstract]

2024 Apr;61(4):1936-1952. PMID: 37819429
J Mol Struct

2026 Feb 13.
Sci Rep

The effects of the Wnt/β-catenin signaling pathway on the in vitro differentiation of rat BMSCs into leydig cells. [Abstract]

2025 Jan 7;15(1):1177. PMID: 39775149
J Biol Chem

The Wnt pathway protein Dvl1 targets Somatostatin receptor 2 for lysosome-dependent degradation. [Abstract]

2023 May;299(5):104645. PMID: 36965619
J Biol Chem

Oligomerization of Frizzled and LRP5/6 protein initiates intracellular signaling for the canonical WNT/β-catenin pathway. [Abstract]

2018 Dec 21;293(51):19710-19724. PMID: 30361437
Mol Pain

EXPRESS: Exacerbation of paclitaxel-induced neuropathic pain behaviors in breast tumor-bearing mice. [Abstract]

2025 Sep 5:17448069251380034. PMID: 40913249
Dis Model Mech

The class A repeats of Lrp5 are required for normal development of bone, retinal vasculature, and mammary gland in vivo. [Abstract]

2025 Sep 11:dmm.052280. PMID: 40932232
Exp Cell Res

WNT/β-catenin signaling promotes VSMCs to osteogenic transdifferentiation and calcification through directly modulating Runx2 gene expression. [Abstract]

2016 Jul 15;345(2):206-17. PMID: 27321958

LGK974 purchased from MedChemExpress. Usage Cited in: Exp Cell Res. 2016 Jul 15;345(2):206-17. [Abstract]

Inhibition of PORCN abolishes Runx2 induction stimulated by β-GP. VSMCs are pretreated with LGK974 (1nM) for 30 min, then incubated with β-GP (10mM) for 24h, and the cell lysates are immunoblotted with antibodies against Runx2 and β-actin, respectively.
Anim Reprod Sci

Pharmacological activation of Wnt/β-catenin signaling is essential for oocyte developmental competence and enhances in vitro embryo production in water buffalo. [Abstract]

2026 Feb:285:108070. PMID: 41365046
bioRxiv

Elongin B orchestrates chromatin and transcriptional programs in H3K27M-mutant diffuse midline glioma. [Abstract]

2026 May 19:2026.05.16.724973. PMID: 42239282
SSRN

2025 Sep 30.
bioRxiv

2025 Sep 10.
bioRxiv

NF2 loss malignantly transforms human pancreatic acinar cells and enhances cell fitness under environmental stress. [Abstract]

2025 May 3:2025.04.29.651251. PMID: 40655016
bioRxiv

Dyr726, a brain-penetrant inhibitor of PI3Kα, Type III receptor tyrosine kinases, and WNT signaling. [Abstract]

2025 Mar 29:2025.03.26.645490. PMID: 40196701
Res Sq

A clinical drug candidate that triggers non-apoptotic cancer cell death. [Abstract]

2025 Feb 11:rs.3.rs-4138879. PMID: 39989975
bioRxiv

2024 October 04.
Pharmacological Research - Modern Chinese Medicine

2024 Sep.
Heidelberg University

2024.
bioRxiv

May 20, 2022.
Research Square Preprint

2021 Aug.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 125 mg/mL (315.31 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 8.33 mg/mL (21.01 mM; ultrasonic and warming and heat to 60°C)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.5224 mL

12.6122 mL

25.2245 mL

5 mM

0.5045 mL

2.5224 mL

5.0449 mL

10 mM

0.2522 mL

1.2612 mL

2.5224 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (6.31 mM); Suspended solution; Need ultrasonic and warming

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.31 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Cell Assay^[1]

HN30 cells and UMSCC cells are used. For TaqMan assay, 2×10⁶ cells per well are plated into six-well cell culture plates and treated with or without LGK974 in amultipoint dose-response. RNA samples are collected after 48 h. For colony formation assays, 2×10³ cells per well are plated into six-well cell culture plates with or without compound treatment. Cells are stained with crystal violet 1 wk later^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]

Mice and Rats^[1]
Nude mice (or nude rats) bearing the mouse mammary tumor virus-Wnt1, HN30, or SNU1076 tumors are randomized according to tumor volume. LGK974 is formulated in 10% (vol/vol) citrate buffer (pH 2.8)/90% (vol/vol) citrate buffer (pH 3.0) or 0.5% MC/0.5% Tween 80 and administered by oral gavage at a dosing volume of 10 μL/g animal body weight. Body weight is monitored daily, and tumor sizes are assessed three times per week after the tumors are palpable. Tumor sizes are determined by using caliper measurements. Tumor volumes are calculated with a formula (length×width×height)/2. The plasma concentrations and exposures of LGK974 in the tumor-bearing nude mice (n=2 per dosing group) are determined on day 14. Blood samples (50 μL) are collected by serial retroorbital sampling at 1, 3, 7, 16, and 24 h postdose. The blood samples are centrifuged, and plasma is separated and frozen until analysis by liquid chromatography/MS/MS. For tolerability studies, LGK974 is administrated to nontumor-bearing Wistar rats one time per day by oral gavage at 3 or 20 mg/kg per day. Necropsies are performed at the end of the study. Tissues are fixed in 10% (vol/vol) neutralbuffered formalin, sectioned, and subjected to H&E staining.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Liu J, et al. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20224-9. [Content Brief]

[2]. Tammela T, et al. A Wnt-producing niche drives proliferative potential and progression in lung adenocarcinoma. Nature. 2017 May 18;545(7654):355-359. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
Ethanol / DMSO	1 mM	2.5224 mL	12.6122 mL	25.2245 mL	63.0612 mL
	5 mM	0.5045 mL	2.5224 mL	5.0449 mL	12.6122 mL
	10 mM	0.2522 mL	1.2612 mL	2.5224 mL	6.3061 mL
	15 mM	0.1682 mL	0.8408 mL	1.6816 mL	4.2041 mL
	20 mM	0.1261 mL	0.6306 mL	1.2612 mL	3.1531 mL
DMSO	25 mM	0.1009 mL	0.5045 mL	1.0090 mL	2.5224 mL
	30 mM	0.0841 mL	0.4204 mL	0.8408 mL	2.1020 mL
	40 mM	0.0631 mL	0.3153 mL	0.6306 mL	1.5765 mL
	50 mM	0.0504 mL	0.2522 mL	0.5045 mL	1.2612 mL
	60 mM	0.0420 mL	0.2102 mL	0.4204 mL	1.0510 mL
	80 mM	0.0315 mL	0.1577 mL	0.3153 mL	0.7883 mL
	100 mM	0.0252 mL	0.1261 mL	0.2522 mL	0.6306 mL

Bioz

Keywords

LGK974

47 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

LGK974

IWP-2

Wnt-C59

ETC-159

XAV-939

Laduviglusib

ICG-001

SB-431542

IWR-1

Palbociclib

LDN193189

Foscenvivint

MSAB

Publications Citing Use of MedChemExpress (MCE) LGK974

Biologische Aktivität

Chemical Information

Publications (47)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Bioz

LGK974

IWP-2

Wnt-C59

ETC-159

XAV-939

Laduviglusib

ICG-001

SB-431542

IWR-1

Palbociclib

LDN193189

Foscenvivint

MSAB

Publications Citing Use of MedChemExpress (MCE) LGK974

Biologische Aktivität

Chemical Information

Publications (47)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

LGK974 Related Classifications

HY-17545 Related Classifications

Bioz